Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05063682
Other study ID # 6678EGFRvIII
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date May 15, 2020
Est. completion date October 2023

Study information

Verified date September 2021
Source Chembrain LTD
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase I trial investigates the efficacy and safety of brain-targeting epidermal growth factor receptor chimeric antigen receptor immune cells (EGFRvIII-CAR T cells) in treating patients with leptomeningeal disease from glioblastoma. T cells are part of the immune system and help the body fight malignant tumours. Immune cells can be genetically modified to destroy brain tumor cells in the laboratory. EGFRvIII -CAR T cells are brain tumor specific and can enter and express its genes in immune cells. Administering patients EGFRvIII -CAR T cells may help to recognize and destroy brain tumor cells in patients with leptomeningeal disease from glioblastoma.


Description:

PRIMARY OBJECTIVES: 1. Examine and describe the safety and feasibility of EGFRvIII-specific hinge-optimized CD3 ζ-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes (EGFRvIII -CAR T cells) through intracerebroventricular (ICV) delivery as adjuvant therapy in participants with EGFRvIII+ leptomeningeal disease from glioblastoma. 2. Determine the activity of EGFRvIII -CAR T cells based on survival rate at 12 months for both arms. SECONDARY OBJECTIVES: 1. Describe persistence, expansion and phenotype of endogenous and EGFRvIII -CAR T cells in peripheral blood (PB), tumor cyst fluid (TCF) and cerebral spinal fluid (CSF) at applicable time points 2. Describe cytokine levels in PB, TCF, and CSF at applicable time points 3. Estimate the rate of disease response by Response Assessment in Neuro-Oncology Leptomeningeal Metastases (RANO LM) criteria 4. Estimate rate of progression free survival at 6 months. Estimate rate of overall survival (OS) at 12 months by study arm. 5. Estimate time to next treatment 6. Evaluate EGFRvIII -CAR T cell persistence in the tumor tissue and the location of the EGFRvIII -CAR T cells with respect to the infusion site. 7. Evaluate biomarkers and cytokine levels OUTLINE: Patients receive EGFRvIII -CAR T cells intracerebroventricular over 15 minutes on day 1. Patients may receive additional cycles based on the persistence of the cells. The patients are followed extensively according to the clinical pharmacology sampling plan; on days 1-30, months 2-12, and three times per year up to 10 years based on response


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 10
Est. completion date October 2023
Est. primary completion date October 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participant has been treated for leptomeningeal metastases after intrathecal chemotherapy and/or radiation OR refuses to undergo additional radiation and/or intrathecal chemotherapy - Participant must have a Karnofsky performance status (KPS) >= 60 - Participant must have a life expectancy of >= 2 months - Women of child-bearing potential must have negative serum pregnancy test and agree to use a reliable form of birth control prior to study entry and for at least two months following study treatment. Male research participants must agree to use a reliable form of birth control and not donate sperm during the study and for at least two months following study treatment - Participant has a histologically confirmed EGFRvII+ (epidermal growth factor receptor) tumor expression by immunohistochemistry (IHC) at the initial tumor presentation or recurrent disease (H-score >= 50) - Participant or legal guardian must have the ability to understand and the willingness to sign a written informed consent Exclusion Criteria: - Research participant requires supplemental oxygen to keep saturation greater than 95% - Research participant requires dialysis - Research participant has uncontrolled seizure activity and/or clinically evident progressive encephalopathy - Failure of research participant or legal guardian to understand the basic elements of the protocol and/or the risks/benefits of participating in the study. - Participant is unwilling to stop treatment with chemotherapy or endocrine therapy and/or radiation one week prior and during the first 4 cycles of the study - Participant has ventriculoperitoneal shunt - Participant has a coagulopathy or bleeding disorder - Participant is HIV+ (human immunodeficiency virus) or has acute CMV (cytomegalovirus) infection - Participant has any uncontrolled illness, including ongoing or active infection; participant has known active hepatitis B or C infection; participants with any signs or symptoms of active infection, positive blood cultures or radiological evidence of infections - Participant has an autoimmune disease that requires constant treatment - Participant has another active malignancy - Participant is unable to undergo a brain magnetic resonance imaging (MRI) - Participant is pregnant or breast feeding

Study Design


Intervention

Biological:
EGFRvIII-specific hinge-optimized CD3 ?-stimulatory/41BB-co-stimulatory Chimeric Antigen Receptor autologous T-lymphocytes
ICV administration

Locations

Country Name City State
Finland Jyväskylä Central Hospital Jyväskylä
Finland University Of Oulu Oulu
India Apollo Hospital New Delhi

Sponsors (4)

Lead Sponsor Collaborator
Chembrain LTD Apollo Hospital, New Delhi, India, Jyväskylä Central Hospital, University of Oulu

Countries where clinical trial is conducted

Finland,  India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of adverse events Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Up to 10 years
Primary Overall survival 12 months
Secondary CAR (chimeric antigen receptor) T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) Measured by absolute number per ul by flow Up to 6 cycles (3 months), at the end of each cycle 1 (each cycle is 14 days)
Secondary Endogenous T cell levels detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) Measured by absolute number per ul by flow Up to 6 cycles (3 months), at the end of each cycle 1 (each cycle is 14 days)
Secondary Cell phenotype detected in tumor cyst fluid (TCF), peripheral blood (PB), and cerebrospinal fluid (CSF) Measured by absolute number per ul by flow Up to 6 cycles (3 months), at the end of each cycle 1 (each cycle is 14 days)
Secondary Cytokine levels (Procartaplex panel) in PB, TCF and CSF Up to 6 cycles (3 months), at the end of each cycle 1 (each cycle is 14 days)
Secondary Disease response Measured by Response Assessment in Neuro-Oncology Criteria (RANO LM). Up to 10 years
Secondary Time to progression Progression defined by RANO LM criteria Up to 10 years
Secondary Overall survival Up to 10 years
Secondary CAR T and endogenous cells detected in tumor tissue Detected in tumor tissue by immunohistochemistry (IHC) Baseline and additional time points according to response (through study completion, up to 10 years by as needed basis)
Secondary EGFRvII (epidermal growth factor receptor) antigen expression levels in tumor tissue. Descriptive statistics will be provided Baseline and additional time points according to response (through study completion, up to 10 years by as needed basis)
See also
  Status Clinical Trial Phase
Recruiting NCT05664243 - A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT02768389 - Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma Early Phase 1
Recruiting NCT05635734 - Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma Phase 1/Phase 2
Completed NCT03679754 - Evaluation of Ad-RTS-hIL-12 + Veledimex in Subjects With Recurrent or Progressive Glioblastoma, a Substudy to ATI001-102 Phase 1
Completed NCT01250470 - Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma Phase 1
Terminated NCT03927222 - Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma Phase 2
Recruiting NCT03897491 - PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma Phase 2
Active, not recruiting NCT03587038 - OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma Phase 1
Completed NCT01922076 - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Phase 1
Recruiting NCT04391062 - Dose Finding for Intraoperative Photodynamic Therapy of Glioblastoma Phase 2
Active, not recruiting NCT03661723 - Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Phase 2
Active, not recruiting NCT02655601 - Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 Phase 2
Completed NCT02206230 - Trial of Hypofractionated Radiation Therapy for Glioblastoma Phase 2
Completed NCT03493932 - Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade Phase 1
Terminated NCT02709889 - Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Completed NCT03018288 - Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Phase 2
Not yet recruiting NCT04552977 - A Trail of Fluzoparil in Combination With Temozolomide in Patients With Recurrent Glioblastoma Phase 2
Withdrawn NCT03980249 - Anti-Cancer Effects of Carvedilol With Standard Treatment in Glioblastoma and Response of Peripheral Glioma Circulating Tumor Cells Early Phase 1
Withdrawn NCT02876003 - Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma Phase 2